PHASE-II EVALUATION OF AMONAFIDE IN ADVANCED SARCOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY

Soft tissue sarcomas are generally resistant to most chemotherapeutic agents, and individuals with advanced disease have a poor prognosis. W e evaluated amonafide, a new drug that has significant activity agains t several tumor cell lines, to determine its activity against sarcomas . Amonafide was administered to 18 patients with advanced soft tissue sarcoma (16 of whom had received prior chemotherapy) at a dose of 300 mg/m(2) over 60 min daily for 5 days. Courses were repeated every 21 d ays. Toxicity was mild, bur no responses were observed. We conclude th at amonafide is not an active agent in previously treated, advanced so ft tissue sarcomas in the dose and schedule utilized.